Forty women were assessed for eligibility at gynaecology clinics in the region , of whom thirty premenopausal women scheduled for hysterectomy due to symptomatic fibroids were randomized to three groups , receiving ( 1 ) GnRH agonist ( Goserelin ) , ( 2 ) GnRH agonist + GnRH antagonist ( Goserelin and Cetrorelix ) or ( 3 ) no treatment .